Institute of Biomedicine and Molecular Immunology, National Research Council-Palermo, Palermo, Italy,
Cell Stress Chaperones. 2013 Nov;18(6):733-43. doi: 10.1007/s12192-013-0424-0. Epub 2013 Apr 12.
Cigarette smoke extracts (CSE) induce oxidative stress, an important feature in chronic obstructive pulmonary disease (COPD), and oxidative stress contributes to the poor clinical efficacy of corticosteroids in COPD patients. Carbocysteine, an antioxidant and mucolytic agent, is effective in reducing the severity and the rate of exacerbations in COPD patients. The effects of carbocysteine on CSE-induced oxidative stress in bronchial epithelial cells as well as the comparison of these antioxidant effects of carbocysteine with those of fluticasone propionate are unknown. The present study was aimed to assess the effects of carbocysteine (10(-4) M) in cell survival and intracellular reactive oxygen species (ROS) production (by flow cytometry) as well as total glutathione (GSH), heme oxygenase-1 (HO-1), nuclear-related factor 2 (Nrf2) expression and histone deacetylase 2 (HDAC-2) expression/activation in CSE-stimulated bronchial epithelial cells (16-HBE) and to compare these effects with those of fluticasone propionate (10(-8) M). CSE, carbocysteine or fluticasone propionate did not induce cell necrosis (propidium positive cells) or cell apoptosis (annexin V-positive/propidium-negative cells) in 16-HBE. CSE increased ROS production, nuclear Nrf2 and HO-1 in 16-HBE. Fluticasone propionate did not modify intracellular ROS production, GSH and HDCA-2 but reduced Nrf2 and HO-1 in CSE-stimulated 16-HBE. Carbocysteine reduced ROS production and increased GSH, HO-1, Nrf2 and HDAC-2 nuclear expression/activity in CSE-stimulated cells and was more effective than fluticasone propionate in modulating the CSE-mediated effects. In conclusion, the present study provides compelling evidences that the use of carbocysteine may be considered a promising strategy in diseases associated with corticosteroid resistance.
香烟烟雾提取物 (CSE) 可诱导氧化应激,这是慢性阻塞性肺疾病 (COPD) 的一个重要特征,氧化应激导致皮质类固醇在 COPD 患者中的临床疗效不佳。卡巴司坦是一种抗氧化剂和黏液溶解剂,可有效降低 COPD 患者的疾病严重程度和恶化率。卡巴司坦对支气管上皮细胞中 CSE 诱导的氧化应激的影响以及与丙酸氟替卡松相比的抗氧化作用尚不清楚。本研究旨在评估卡巴司坦 (10(-4) M) 对细胞存活率和细胞内活性氧 (ROS) 产生的影响 (通过流式细胞术) 以及总谷胱甘肽 (GSH)、血红素加氧酶-1 (HO-1)、核相关因子 2 (Nrf2) 表达和组蛋白去乙酰化酶 2 (HDAC-2) 在 CSE 刺激的支气管上皮细胞 (16-HBE) 中的表达/激活,并将这些作用与丙酸氟替卡松 (10(-8) M) 进行比较。CSE、卡巴司坦或丙酸氟替卡松在 16-HBE 中均未诱导细胞坏死 (碘化丙啶阳性细胞) 或细胞凋亡 (膜联蛋白 V 阳性/碘化丙啶阴性细胞)。CSE 增加了 16-HBE 中的 ROS 产生、核 Nrf2 和 HO-1。丙酸氟替卡松不改变细胞内 ROS 产生、GSH 和 HDCA-2,但可减少 CSE 刺激的 16-HBE 中的 Nrf2 和 HO-1。卡巴司坦降低了 CSE 刺激细胞中的 ROS 产生并增加了 GSH、HO-1、Nrf2 和 HDAC-2 的核表达/活性,并且在调节 CSE 介导的作用方面比丙酸氟替卡松更有效。综上所述,本研究提供了令人信服的证据,表明使用卡巴司坦可能被认为是一种有前途的策略,可用于治疗与皮质类固醇耐药相关的疾病。